Literature DB >> 17409315

Neutralization of macrophage-stimulating protein ameliorates renal injury in anti-thy 1 glomerulonephritis.

Teresa Rampino1, Grazia Soccio, Marilena Gregorini, Cristina Guidetti, Maddalena Marasà, Milena Maggio, Vincenzo Panichi, Massimiliano Migliori, Carmelo Libetta, Antonio Dal Canton.   

Abstract

Macrophage-stimulating protein (MSP) is a scatter factor that causes cell proliferation and migration, and receptor origin nantaise (RON) is its receptor. RON is expressed in macrophages and mesangial cells, and MSP is produced by renal tubular cells. This study investigated whether MSP/RON participate in the pathogenesis of anti-Thy 1 nephritis, a glomerular disease that is characterized by invasion of circulating monocytes into glomeruli and migration and proliferation of mesangial cells. In vivo, renal function and histopathology were studied in rats that had anti-Thy 1 disease and were untreated and treated with a neutralizing anti-MSP antibody. In vitro, whether monocytes express RON and whether MSP has a chemotactic effect on monocytes were studied. In vivo, in anti-Thy 1 disease, MSP was expressed de novo in glomeruli, and neutralization of MSP attenuated the rise in serum creatinine and proteinuria, stopped glomerular neutrophil and monocyte influx, protected from glomerular injury, and lessened mesangial cell overgrowth. In vitro, unstimulated monocytes did not express RON, but the stimulation with LPS induced de novo RON expression. LPS-stimulated monocytes were attracted by MSP. These results demonstrate a pathogenic role of the MSP/RON system in anti-Thy 1 nephritis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17409315     DOI: 10.1681/ASN.2006060680

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  7 in total

1.  Hepatocyte growth factor-like protein is a positive regulator of early mammary gland ductal morphogenesis.

Authors:  Devikala Gurusamy; Sasha J Ruiz-Torres; Abby L Johnson; Dana A Smith; Susan E Waltz
Journal:  Mech Dev       Date:  2014-07-15       Impact factor: 1.882

Review 2.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

3.  Mesenchymal stromal cells reset the scatter factor system and cytokine network in experimental kidney transplantation.

Authors:  Marilena Gregorini; Francesca Bosio; Chiara Rocca; Valeria Corradetti; Teresa Valsania; Eleonora Francesca Pattonieri; Pasquale Esposito; Giulia Bedino; Chiara Collesi; Carmelo Libetta; Francesco Frassoni; Antonio Dal Canton; Teresa Rampino
Journal:  BMC Immunol       Date:  2014-10-03       Impact factor: 3.615

4.  RON kinase inhibition reduces renal endothelial injury in sickle cell disease mice.

Authors:  Alfia Khaibullina; Elena A Adjei; Nowah Afangbedji; Andrey Ivanov; Namita Kumari; Luis E F Almeida; Zenaide M N Quezado; Sergei Nekhai; Marina Jerebtsova
Journal:  Haematologica       Date:  2018-03-08       Impact factor: 9.941

Review 5.  Stem cell-based cell therapy for glomerulonephritis.

Authors:  Meiling Jin; Yuansheng Xie; Qinggang Li; Xiangmei Chen
Journal:  Biomed Res Int       Date:  2014-06-09       Impact factor: 3.411

6.  Macrophage Stimulating Protein Enhances Hepatic Inflammation in a NASH Model.

Authors:  Jieyi Li; Dipanjan Chanda; Patrick J van Gorp; Mike L J Jeurissen; Tom Houben; Sofie M A Walenbergh; Jacques Debets; Yvonne Oligschlaeger; Marion J J Gijbels; Dietbert Neumann; Ronit Shiri-Sverdlov
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

Review 7.  MSP-RON Pathway: Potential Regulator of Inflammation and Innate Immunity.

Authors:  Lingtong Huang; Xueling Fang; Danrong Shi; Shuhao Yao; Weifang Wu; Qiang Fang; Hangping Yao
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.